Trent Welsh
Contributor since: 2016
Articles
Pfizer's Data Release Shows That It Still Is Light-Years Behind Sarepta In DMD
50% Y/Y Sales Growth And Rapid Retail Expansion Could Be Just The Start For Amazon
Buying AT&T Again After My Price Target Was Hit
Virgin Galactic Just Did Something Really Smart
Arrowhead Pharmaceuticals Long-Term Intact As Shorts Finish Taking Profits
Jim Cramer's Sold The Clorox Bubble Which Opened The Door For New Investors
March Flowers Could Bring MiMedx Showers Of Shareholder Returns
Buying Hopes And Prayers And Virgin Galactic
Sold 25% Of My Actively Managed Portfolio And Bought Clorox And 3M, Here's Why
Buying The World Wrestling Entertainment Dip, Ohhh Yeah
Hi-Crush Could Be Profitable Next Quarter
Selling The Latest Sprint Pop, Again
Jacobs Engineering: An Unassuming Space Race Play
American Tower: The Right REIT Right Now
Casimersen Is A Lead Catalyst For Sarepta Therapeutics As A Top 2020 Stock Pick
Impressive Debt Retirement Could Be The Catalyst For Significant Shareholder Growth For Macy's In The Coming Years
Buy Arrowhead Pharmaceuticals Now At Near The Institutional Discount
Sarepta: Roche Partnership After The FDA's Turnaround Forms The Basis For A $158.59 Near-Term Price Target
10 Reasons To Buy MiMedx Stock Today
There Is A Reason Investors Are Getting Excited About Summit Therapeutics Again
Sarepta Therapeutics Is Bottoming Out
MiMedx - All In On This Home Run Stock
Selling My AT&T After A Great Run Before The Elliot-Fueled Hype Train Gets Derailed
Jacobs Engineering: Continues To Outperform As A Transformational Cinderella Story
Doubling Down On Macy's Ridiculous 10% Dividend Yield
After The Dust Has Settled, Key Sarepta Therapeutics Insiders Are Still Buying Shares And So Should Investors
Solid Biosciences Looks Like An Obvious Sell
Selling Altaba To Buy Alibaba
Catching The World Wrestling Entertainment Falling Knife
BioTelemetry: A Strong Buy At 52-Week Lows As A Key Part Of Apple's Heart Study Innovation
Sarepta Therapeutics - Buy The Latest 'Bad News'
Arrowhead Pharmaceuticals: Highlights Of A Terrific Earnings Call